Barrera, Cristian
Corredor, Germán http://orcid.org/0000-0003-3002-0937
Viswanathan, Vidya Sankar
Ding, Ruiwen
Toro, Paula
Fu, Pingfu http://orcid.org/0000-0002-2334-5218
Buzzy, Christina
Lu, Cheng
Velu, Priya
Zens, Philipp
Berezowska, Sabina http://orcid.org/0000-0001-5442-9791
Belete, Merzu
Balli, David
Chang, Han
Baxi, Vipul
Syrigos, Konstantinos
Rimm, David L. http://orcid.org/0000-0001-5820-4397
Velcheti, Vamsidhar
Schalper, Kurt
Romero, Eduardo
Madabhushi, Anant http://orcid.org/0000-0002-5741-0399
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (1R43EB028736-01)
U.S. Department of Health & Human Services | NIH | National Center for Research Resources (1 C06 RR12463-01)
California Breast Cancer Research Program (W81XWH-19-1-0668)
Article History
Received: 31 October 2022
Accepted: 19 May 2023
First Online: 1 June 2023
Competing interests
: A.M. is an equity holder in Elucid Bioimaging, Picture Health and in Inspirata Inc. He is also a scientific advisory consultant for Aiforia Inc, Picture Health and SimbioSys. In addition, he has served as a scientific advisory board member for Inspirata Inc, Astrazeneca, Bristol-Myers-Squibb and Merck. He also has sponsored research agreements with Philips, Astrazeneca, Bristol-Myers Squibb, Boehringer-Ingelheim and Eli-Lilly. His technology has been licensed to Elucid Bioimaging and Picture Health. He also consults for Castle Biosciences, Biohme Inc. and SimbioSys. He is also involved in a NIH (National Institutes of Health) U24 grant with PathCore Inc, and 3 different R01 grants with Inspirata Inc. Kurt Schalper received research funding from Genoptix/Navigate (Novartis), Tesaro, Moderna Therapeutics, Takeda, Surface Oncology, Pierre-Fabre Research Institute, Merck, Bristol-Myers Squibb, AstraZeneca, and Eli Lilly. In addition, he has received honoraria for consultant/advisory roles from Celgene, Moderna Therapeutics, Shattuck Labs, Pierre-Fabre, AstraZeneca, EMD Serono, Ono Pharmaceuticals, Clinica Alemana de Santiago, Dynamo Therapeutics, PeerView, Abbvie, Fluidigm, Takeda/Millenium Pharmaceuticals, Merck, Bristol-Myers Squibb, Agenus, and Torque Therapeutics. D.L.R. has served as an advisor for AstraZeneca, Agendia, Amgen, BMS, Cell Signaling Technology, Cepheid, Danaher, Daiichi Sankyo, Novartis, GSK, Konica Minolta, Merck, NanoString, PAIGE.AI, Perkin Elmer, Regeneron, Roche, Sanofi, Ventana and Ultivue. Amgen, Cepheid, Konica Minolta, NavigateBP, NextCure, and Lilly have funded research in his lab. V.B., D.B., and M.B. are currently employees of Bristol-Myers Squibb. S.B. received research funding from Roche and Basilea (to institution) and has served as a scientific advisory board member for Eli Lilly. The remaining authors declare no competing interests.